Adjuvant Atezolizumab Does Not Show Disease-Free Survival Benefit in High-Risk Bladder Cancer

TOP - September 2020 Vol 13, No 5 - Bladder Cancer

Adjuvant therapy with atezolizumab (Tecentriq) did not meet the primary end point of disease-free survival (DFS) in patients with muscle-invasive urothelial cancer (MIUC) at high risk for recurrence versus observation alone in the primary analysis of the IMvigor010 trial.

At a median follow-up of 21.9 months, the rate of DFS was identical in both arms of the trial: 52%. Median DFS was 19.4 months with atezolizumab versus 16.6 months with observation alone. The results were reported at the ASCO 2020 virtual annual meeting.

“The difference in median disease-free survival did not translate to a significant hazard ratio,” said lead investigator Maha H.A. Hussain, MD, FACP, FASCO, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL.

“IMvigor010 was a completely negative trial. No disease-free survival benefit was found for adjuvant atezolizumab,” said discussant of this trial, Toni K. Choueiri, MD, Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA. “Adjuvant single-agent atezolizumab is not advised in unselected MIUC, despite there being more than 50% of high-risk patients in this trial.”

Experts expressed disappointment at the result, noting that checkpoint inhibitor therapy does have benefit in the setting of metastatic urothelial carcinoma, but no good explanation for this difference was proposed.

Study Details

IMvigor010 enrolled 809 patients with MIUC who were at high risk for disease recurrence after primary resection with radical cystectomy or nephroureterectomy with lymph node dissection at least 14 weeks before study randomization. No postsurgical adjuvant radiation or chemotherapy was allowed. Patients who did not receive neoadjuvant chemotherapy were either ineligible for or declined cisplatin therapy.

Patients were randomized in a 1:1 ratio to adjuvant atezolizumab 1200 mg once every 3 weeks for a maximum of 16 cycles or 1 year of observation every 3 weeks. At 18 months, DFS rate was 51% for atezolizumab and 49% for observation, and PD-L1 expression status had no effect on DFS.

Subgroup analysis did not show any trend favoring atezolizumab over observation, regardless of disease stage, receipt of neoadjuvant chemotherapy, nodal status, and geographic site. The overall survival data are not yet mature, and further follow-up is needed.

The safety profile of atezolizumab was similar to what had been reported in advanced urothelial cancer. Adverse events of any cause were reported in 94% of the atezolizumab group and 79% of the placebo group. Grades 1 and 2 adverse events of special interest occurred more often with atezolizumab and were mainly pruritus, fatigue, diarrhea, and rash.

Serious events (31% vs 18%, respectively) and grade 3 or 4 events of any cause were also more common with atezolizumab (37% vs 20%, respectively).

The rate of adverse events leading to discontinuation of atezolizumab (mostly skin and gastrointestinal events) was 16%. Dose interruptions were needed in 33% of patients. “The rate of treatment discontinuations due to adverse events was higher than in other studies of atezolizumab in this setting,” Dr Hussain said.

Related Items
Sacituzumab plus Pembrolizumab Shows Encouraging Antitumor Activity in Metastatic Urothelial Cancer
Patricia Stewart
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GU 2022 Highlights
Circulating Tumor DNA Profiling May Result in Improved Detection and Treatment of CNS Lymphoma
Patricia Stewart
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASH 2021 Highlights
Pembrolizumab plus Chemotherapy Prolongs Survival in Patients with Triple-Negative Breast Cancer and PD-L1 Combined Positive Score ≥10
Patricia Stewart
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in SABCS
Study Finds 1 in 6 Patients with Cancer Experience “Long-Haul” COVID-19
Patricia Stewart
TOP - March 2022 Vol 15, No 2 published on February 28, 2022 in COVID-19 & Cancer
Adagrasib Shows Promising Activity in Patients with KRASᴳ¹²ᶜ-Mutated Metastatic Colorectal Cancer
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Colorectal Cancer
Antibody–Drug Conjugate Shows Promising Activity in Patients with Advanced or Metastatic EGFR Mutation–Positive NSCLC
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Lung Cancer
Abiraterone Added to Androgen-Deprivation Therapy Significantly Improves Metastasis-Free Survival in Patients with High-Risk Prostate Cancer
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Prostate Cancer
Amivantamab plus Lazertinib Combo Improves Response in Osimertinib-Resistant EGFR-Positive NSCLC
Patricia Stewart
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Lung Cancer
ALK-Targeted Therapy Appears Beneficial in Patients with Adult-Onset Neuroblastoma
Patricia Stewart
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Neuroblastoma
Sotorasib Shows Encouraging Activity in Patients with NSCLC and KRAS p.G12C Mutation
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Last modified: July 22, 2021